

JURISDICTION SPECIFIC MEDICARE PART B

FEIBA (anti-inhibitor coagulant complex)

POLICY

I. COVERED USES

The indications below are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

Hemophilia A and B with inhibitors for:

- A. Control and prevention of bleeding episodes
- B. Perioperative management
- C. Routine prophylaxis to prevent or reduce the frequency of bleeding episodes

All other indications will be assessed on an individual basis. Submissions for indications other than those enumerated in this policy should be accompanied by supporting evidence from Medicare approved compendia.

II. DOCUMENTATION

The following documentation must be available in a legible format with patient identification information (e.g., complete name and dates of service) and signature of physician or non-physician practitioner responsible for and providing care to the member, upon request, for all submissions:

- A. The submitted medical record must support the use of the selected ICD-10-CM codes. The submitted CPT/HCPCS code must describe the service performed.
- B. The medical record documentation must support the medical necessity of the services as stated in this policy.

III. CRITERIA FOR APPROVAL

A. Hemophilia A with Inhibitors

Authorization of 12 months may be granted for treatment of hemophilia A with inhibitor antibodies when the member has major bleeding episodes that fail to respond to other, less expensive therapies.

B. Hemophilia B with Inhibitors

Authorization of 12 months may be granted for treatment of hemophilia B with inhibitors.

IV. REFERENCES

1. Hemophilia Factor Products LCD (L35111) Version R16. Available at: <https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx>. Accessed December 21, 2020.
2. Billing and Coding: Hemophilia Factor Products (A56433) Version R2. Available at: <https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx>. Accessed December 21, 2020.

Reference number(s)
4031-A

3. FEIBA [package insert]. Lexington, MA: Baxalta US, Inc.; February 2020.
4. Medicare National Coverage Determinations (NCD) Manual. Chapter 1, Part 2, Section 110.3 Anti-Inhibitor Coagulant Complex (AICC). (Rev. 1, Effective: 10-03-03). <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/bp102c15.pdf> Accessed December 2020.